Clinical bottom line
Emerging systemic treatments, notably dupilumab, show promising efficacy and safety profiles for managing chronic pruritic dermatitis in patients with atopic comorbidities such as asthma and allergic rhinitis. Current evidence supports dupilumab’s role in reducing disease severity and pruritus, improving quality of life, and maintaining a favorable safety profile even in older adults and those with intrinsic or extrinsic atopic phenotypes. However, data remain limited for newer agents and for long-term outcomes specifically in patients with multiple atopic conditions, warranting cautious interpretation and individualized clinical decision-making.
What the evidence shows
Dupilumab, an IL-4 receptor alpha antagonist, has been extensively studied in atopic dermatitis (AD) populations, including those with coexisting atopic comorbidities. Koskeridis et al. (2022) conducted a systematic review and meta-analysis demonstrating that dupilumab significantly improves clinical severity scores and pruritus in AD patients, with consistent benefits observed across subgroups with asthma and allergic rhinitis. Zhao et al. (2025) further reported that dupilumab is effective and well tolerated in older patients with both intrinsic and extrinsic AD, regardless of the presence of atopic comorbidities, suggesting broad applicability.
Additional real-world evidence from Case Medical Research (2019) supports the safety and efficacy of dupilumab in moderate to severe chronic AD, including patients with complex atopic profiles. This aligns with Faculty Opinions’ 2019 recommendation emphasizing dupilumab’s relative efficacy compared to other systemic agents, highlighting its favorable benefit-risk balance.
Fang Yongxing et al. (2023) explored sensitization patterns in AD patients with atopic comorbidities, underscoring the heterogeneity of immune responses and the potential for targeted therapies to address overlapping pathogenic pathways. Ariëns et al. (unpublished but cited 2023) discuss the evolving landscape of systemic treatments, noting that emerging agents targeting JAK-STAT signaling and other pathways may offer additional options but require further validation in this subgroup.
Caveats and uncertainty
Despite encouraging data, several uncertainties remain. Most clinical trials and meta-analyses focus on AD broadly, with limited stratification by specific atopic comorbidities or detailed phenotyping, which may affect generalizability. Long-term safety data beyond two years are sparse, particularly in older adults and those with multiple atopic diseases. The impact of emerging systemic agents beyond dupilumab, such as JAK inhibitors or novel biologics, in patients with complex atopic profiles is not yet well characterized.
Moreover, heterogeneity in study designs and outcome measures complicates direct comparisons. The role of intrinsic versus extrinsic AD phenotypes in treatment response also warrants further investigation, as highlighted by Zhao et al. (2025). Real-world adherence and cost-effectiveness data remain limited, factors crucial for clinical decision-making.
How this may change practice
Clinicians managing chronic pruritic dermatitis in patients with atopic comorbidities should consider dupilumab as a frontline systemic option given its demonstrated efficacy and safety. Recognition of the overlapping immunopathology in atopic multimorbidity supports a more integrated treatment approach. Careful patient selection, including assessment of age, comorbid conditions, and AD phenotype, can optimize outcomes.
Emerging systemic therapies may expand options in the near future, but current evidence supports prioritizing dupilumab while monitoring for long-term safety and effectiveness. Multidisciplinary collaboration with allergy and pulmonology specialists may enhance management of atopic multimorbidity. Ongoing research and post-marketing surveillance will be essential to refine treatment algorithms and identify biomarkers predictive of response.